Tumor antigens such as EGFR, CTLA4, CD20, CD30, CD52, erbB2, and VEGF have all been investigated for targeted drug delivery into the brain.30,46,47 Various antiangiogenic drugs have been utilized in GBM therapy to target the vascular endothelial growth factor (VEGF), reducing excessive vascularization of gliomas, and increasing tumor survival rates. This evidence concerns the gene EGFR and glioblastoma.